Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

Area of Science:

• Hematology
• Gene Therapy
• Cellular Therapy

Background:

• Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are debilitating blood disorders with limited treatment options.
• Allogeneic hematopoietic stem cell transplant (HSCT) is curative but limited by donor availability and transplant-related complications like graft-versus-host disease (GVHD).
• Gene therapy (GT) presents a curative alternative by modifying a patient's own stem cells, offering a potentially safer and more accessible treatment.

Purpose of the Study:

• To review the clinical studies supporting FDA approvals for gene therapies for SCD and TDT.
• To comment on the transfusion and stem cell collection regimens used in these studies.
• To identify areas for improvement in pre-transfusion and stem collection protocols for gene therapy.

Main Methods:

• Appraisal of pivotal clinical trial data submitted for FDA approval of gene therapies.
• Analysis of transfusion strategies and hematopoietic stem and progenitor cell (HSPC) collection procedures.
• Literature review focusing on the efficacy and safety of approved gene therapies.

Main Results:

• FDA has approved multiple gene therapies for SCD and TDT, including lovotibeglogene autotemcel, betibeglogene autotemcel, and exagamglogene autotemcel.
• The studies supporting these approvals highlight the potential of GT to provide a functional cure.
• Variability exists in current transfusion and stem collection practices, suggesting a need for standardization and optimization.

Conclusions:

• Gene therapy represents a significant advancement, offering a curative potential for SCD and TDT patients.
• Optimizing pre-transfusion regimens and stem cell collection processes is crucial for maximizing the success of gene therapy.
• Further research is warranted to refine protocols and ensure widespread accessibility of these transformative treatments.